路透5月14日 - 青鸟生物BLUE.O和凯雷投资集团CG.O及SK Capital Partners周三表示，这两家私募股权公司已提出每股5美元的预付款收购这家基因治疗公司。
股东可以选择接受新报价或之前的每股3美元报价，如果蓝鸟公司达到某些销售里程碑，股东还可以额外获得6.84美元。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.